AVRO 1330% upside potential according to this analyst!!!
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc . have the largest stakes in the company with an average around $9 per share.
On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.
The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.
What are we waiting for?
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc . have the largest stakes in the company with an average around $9 per share.
On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.
The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.
What are we waiting for?
BUY-SELL indicators: https://tradingindicators.store/ ASK FOR A FREE TRIAL!!!
How to install the indicators: https://www.youtube.com/watch?v=VsJ3V3Uczsk&t=2s&ab_channel=TradingIndicators
My Best Stock Picks: https://www.patreon.com/tradingindicators
How to install the indicators: https://www.youtube.com/watch?v=VsJ3V3Uczsk&t=2s&ab_channel=TradingIndicators
My Best Stock Picks: https://www.patreon.com/tradingindicators